Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.

被引：2
|
作者：
Jindy, Tanya
Jiang, Cindy Y.
Alhalabi, Omar
Nguyen, Charles B.
Nizam, Amanda
Basu, Arnab
Bilen, Mehmet Asim
Zakharia, Yousef
Milowsky, Matthew I.
Brown, Jason R.
Kilari, Deepak
Emamekhoo, Hamid
Hoimes, Christopher J.
Khaki, Ali Raza
Gupta, Shilpa
Grivas, Petros
Bellmunt, Joaquim
Campbell, Matthew T.
Alva, Ajjai Shivaram
Koshkin, Vadim S.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Hematol Oncol Fellowship, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
[4] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA
[5] Cleveland Clin, Cleveland, OH USA
[6] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA
[7] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[8] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA
[9] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[10] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[11] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI USA
[12] Univ Wisconsin, Madison, WI USA
[13] Duke Univ, Duke Canc Inst, Durham, NC USA
[14] Stanford Univ, Sch Med, Dept Med, Div Oncol, Stanford, CA USA
[15] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA
[16] Univ Washington, Div Hematol & Oncol, Seattle, WA USA
[17] Fred Hutchinson Canc Ctr, Seattle, WA USA
[18] Dana Farber Canc Inst, Boston, MA USA
[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[20] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI USA
[21] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-183-138-12099; 261-492-3532-2370-7650-2700; 261-566-9263; 4; 2; 3224; 3; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.652
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：652 / 652
页数：1
相关论文
共 50 条
  • [31] Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma
    Minato, Akinori
    Takaba, Tomohisa
    Sugita, Yoshihiro
    Kaneko, Yuya
    Hongyo, Ryota
    Tanaka, Toshinobu
    Bando, Taro
    Sugi, Takaomi
    Mizushima, Yui
    Matsukawa, Takuo
    Jojima, Kazumasa
    Higashijima, Katsuyoshi
    Nagata, Yujiro
    Tomisaki, Ikko
    Kashiwagi, Eiji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [32] Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study
    Rikiya Taoka
    Masaki Kamada
    Kazuyoshi Izumi
    Ryuta Tanimoto
    Kei Daizumoto
    Yushi Hayashida
    Katsutoshi Uematsu
    Hironobu Arai
    Takeshi Sano
    Ryoichi Saito
    Hiromi Hirama
    Toshihiro Kobayashi
    Tomoko Honda
    Yu Osaki
    Yohei Abe
    Hirohito Naito
    Yoichiro Tohi
    Yuki Matsuoka
    Takuma Kato
    Homare Okazoe
    Nobufumi Ueda
    Mikio Sugimoto
    International Journal of Clinical Oncology, 2024, 29 : 602 - 611
  • [33] Enfortumab Vedotin Nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma
    Pace, Amanda
    Brower, Blaine
    Conway, Dawn
    Leis, Dayna
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2021, 25 (02) : E1 - E9
  • [34] Retrospective analysis of urothelial carcinoma treated with enfortumab vedotin at our institution
    Imai, Toru
    Kita, Shosuke
    Shimoi, Tatsunori
    Yazaki, Shu
    Tokura, Momoko
    Kawachi, Asuka
    Okuma, Hitomi S.
    Nakamura, Eijiro
    Arakaki, Motoko
    Saito, Ayumi
    Yamamoto, Kasumi
    Maejima, Aiko
    Kojima, Yuki
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Noguchi, Emi
    Matsui, Yoshiyuki
    Fujiwara, Yasuhiro
    Yonemori, Kan
    ANNALS OF ONCOLOGY, 2023, 34 : S1417 - S1417
  • [35] Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study
    Taoka, Rikiya
    Kamada, Masaki
    Izumi, Kazuyoshi
    Tanimoto, Ryuta
    Daizumoto, Kei
    Hayashida, Yushi
    Uematsu, Katsutoshi
    Arai, Hironobu
    Sano, Takeshi
    Saito, Ryoichi
    Hirama, Hiromi
    Kobayashi, Toshihiro
    Honda, Tomoko
    Osaki, Yu
    Abe, Yohei
    Naito, Hirohito
    Tohi, Yoichiro
    Matsuoka, Yuki
    Kato, Takuma
    Okazoe, Homare
    Ueda, Nobufumi
    Sugimoto, Mikio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (05) : 602 - 611
  • [36] Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study
    Fukuokaya, Wataru
    Koike, Yuhei
    Yata, Yuji
    Komura, Kazumasa
    Uchimoto, Taizo
    Tsujino, Takuya
    Saruta, Masanobu
    Takahara, Kiyoshi
    Fujita, Kazutoshi
    Minami, Takafumi
    Adachi, Takahiro
    Hirasawa, Yosuke
    Hashimoto, Takeshi
    Ohno, Yoshio
    Uemura, Hirotsugu
    Shiroki, Ryoichi
    Azuma, Haruhito
    Kimura, Takahiro
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (04) : 342 - 347
  • [37] Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
    Sayegh, Nicolas
    Jo, Yeonjung
    Gebrael, Georges
    Tripathi, Nishita
    Chigarira, Beverly
    Srivastava, Ayana
    Nordblad, Blake
    Dal, Emre
    Chehade, Chadi Hage
    Mahlow, Jon
    Maughan, Benjamin L.
    Gupta, Sumati
    Agarwal, Neeraj
    Swami, Umang
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [38] PERIPHERAL NEUROPATHY AND NERVE ELECTROPHYSIOLOGICAL CHANGES WITH ENFORTUMAB VEDOTIN IN PATIENTS WITH ADVANCED UROTHELIAL CARCINOMA: A PROSPECTIVE MULTICENTER COHORT STUDY
    Taoka, Rikiya
    Kamada, Masaki
    Izumi, Kazuyoshi
    Tanimoto, Ryuta
    Daizumoto, Kei
    Hayashida, Yushi
    Uematsu, Katsutoshi
    Arai, Hironobu
    Sano, Takeshi
    Saito, Ryoichi
    Hirama, Hiromi
    Kobayashi, Toshihiro
    Sugimoto, Mikio
    JOURNAL OF UROLOGY, 2024, 211 (05): : E868 - E869
  • [39] Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis
    Wang, Leibo
    Shi, Guanyu
    Zhao, Guoqiang
    He, Wei
    Cen, Zhuangding
    Xu, Feng
    ANTI-CANCER DRUGS, 2023, 34 (04) : 473 - 478
  • [40] Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
    Kawahara, Takashi
    Hasizume, Akihito
    Uemura, Koichi
    Yamaguchi, Katsuya
    Ito, Hiroki
    Takeshima, Teppei
    Hasumi, Hisashi
    Teranishi, Jun-ichi
    Ousaka, Kimito
    Makiyama, Kazuhide
    Uemura, Hiroji
    CANCERS, 2023, 15 (17)
12345